Novel Major Depression Drug Misses in Phase 3 Topline Results Novel Major Depression Drug Misses in Phase 3 Topline Results

The novel drug SAGE-217 did not meet its primary outcome of reduction in depression scores at day 15 in the phase 3 MOUNTAIN trial, but additional analyses show"supportive" data, researchers say.Medscape Medical News
Source: Medscape Psychiatry Headlines - Category: Psychiatry Tags: Psychiatry News Source Type: news
More News: Depression | Psychiatry